YES1 and Alzheimer disease: However, dasatinib can inhibit numerous non-receptor tyrosine kinases including Src, Lyn, Fyn, Yes, and Bcr/Abl raising the possibility that long-term treatment, as might be required for treating AD patients, would suffer from adverse consequences [51, 52].